Poseida Therapeutics Stock Forecast, Price & News

-0.26 (-2.75 %)
(As of 06/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume200,668 shs
Average Volume312,925 shs
Market Capitalization$572.45 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PSTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Poseida Therapeutics logo

About Poseida Therapeutics

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.69 out of 5 stars

Medical Sector

327th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

42nd out of 198 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Poseida Therapeutics (NASDAQ:PSTX) Frequently Asked Questions

Is Poseida Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Poseida Therapeutics stock.
View analyst ratings for Poseida Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Poseida Therapeutics?

Wall Street analysts have given Poseida Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Poseida Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Poseida Therapeutics' next earnings date?

Poseida Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 19th 2021.
View our earnings forecast for Poseida Therapeutics

How were Poseida Therapeutics' earnings last quarter?

Poseida Therapeutics, Inc. (NASDAQ:PSTX) announced its earnings results on Tuesday, May, 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.64) by $0.02.
View Poseida Therapeutics' earnings history

What price target have analysts set for PSTX?

4 analysts have issued 12 month target prices for Poseida Therapeutics' shares. Their forecasts range from $20.00 to $40.00. On average, they expect Poseida Therapeutics' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 225.7% from the stock's current price.
View analysts' price targets for Poseida Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Poseida Therapeutics' key executives?

Poseida Therapeutics' management team includes the following people:
  • Dr. Eric M. Ostertag, CEO & Director (Age 48, Pay $858.68k)
  • Mr. Mark J. Gergen, Pres, Chief Bus. Officer & Director (Age 58, Pay $636.49k)
  • Mr. Harry J. Leonhardt, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 64, Pay $494.54k)
  • Ms. Johanna M. Mylet CPA, Sr. VP of Fin. (Age 34)
  • Mr. Kerry D. Ingalls, Chief Operating Officer (Age 59)
  • Sarah Thailing, Director of Corp. Communications & IR
  • Ms. Kristin Martin, Chief HR Officer
  • Dr. Devon J. Shedlock, Sr. VP of R&D
  • Dr. Matthew A. Spear, Chief Medical Officer (Age 54)
  • Mr. Jeff Knight, Sr. VP of Portfolio Management & Corp. Operations

Who are some of Poseida Therapeutics' key competitors?

What other stocks do shareholders of Poseida Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW), OPKO Health (OPK), (OSTK), Sorrento Therapeutics (SRNE) and SSR Mining (SSRM).

When did Poseida Therapeutics IPO?

(PSTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair acted as the underwriters for the IPO.

What is Poseida Therapeutics' stock symbol?

Poseida Therapeutics trades on the NASDAQ under the ticker symbol "PSTX."

Who are Poseida Therapeutics' major shareholders?

Poseida Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.55%), Millennium Management LLC (2.84%), Schonfeld Strategic Advisors LLC (0.67%), Geode Capital Management LLC (0.65%), JPMorgan Chase & Co. (0.50%) and Advisory Services Network LLC (0.41%). Company insiders that own Poseida Therapeutics stock include Eric Ostertag, Matthew A Spear and Sean Murphy.
View institutional ownership trends for Poseida Therapeutics

Which institutional investors are selling Poseida Therapeutics stock?

PSTX stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, and Goldman Sachs Group Inc.. Company insiders that have sold Poseida Therapeutics company stock in the last year include Eric Ostertag, and Matthew A Spear.
View insider buying and selling activity for Poseida Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Poseida Therapeutics stock?

PSTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Schonfeld Strategic Advisors LLC, JPMorgan Chase & Co., Millennium Management LLC, Advisory Services Network LLC, Pura Vida Investments LLC, Geode Capital Management LLC, and Nuveen Asset Management LLC.
View insider buying and selling activity for Poseida Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Poseida Therapeutics?

Shares of PSTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Poseida Therapeutics' stock price today?

One share of PSTX stock can currently be purchased for approximately $9.21.

How much money does Poseida Therapeutics make?

Poseida Therapeutics has a market capitalization of $572.45 million. The company earns $-129,770,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis.

How many employees does Poseida Therapeutics have?

Poseida Therapeutics employs 206 workers across the globe.

What is Poseida Therapeutics' official website?

The official website for Poseida Therapeutics is

Where are Poseida Therapeutics' headquarters?

Poseida Therapeutics is headquartered at 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Poseida Therapeutics?

Poseida Therapeutics' mailing address is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The company can be reached via phone at 858-779-3100.

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.